Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exenatide + insulin
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
A combination therapy for type 2 diabetes mellitus that pairs exenatide, a GLP-1 receptor agonist, with insulin. Exenatide works by stimulating insulin release from pancreatic beta cells in a glucose-dependent manner, slowing gastric emptying, and reducing glucagon secretion. When combined with insulin, particularly long-acting insulin like insulin glargine (Lantus), this therapy can provide complementary mechanisms for glycemic control. The combination has been shown to reduce HbA1c levels by approximately 1.1 percentage points. However, exenatide should not be combined with rapid-acting or short-acting insulin analogs.
02
Targets
GLP1R (GLP-1R)INSR (Insulin receptor)
Beyond the preview
Go deeper on exenatide + insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exenatide + insulin.